2026年2月13日，泽璟制药披露接待调研公告，公司于2月2日至2月10日接待淡水泉、农银汇理、安信基 金、华安基金、建信资产、平安基金等28家机构调研。 调研情况显示，泽璟制药与艾伯维就ZG006达成全球开发及商业化战略合作与许可选择权协议，艾伯维 获大中华区以外地区独家权利，泽璟保留区内权利；泽璟已收到1亿美元首付款，还可获最高6000万美 元近期里程碑及许可选择付款，若选择权行使另有最高10．75亿美元里程碑付款和高个位数到中双位数 阶梯特许权使用费。ZG006正推进单药及联合用药治疗小细胞肺癌、神经内分泌癌等临床试验，包括关 键及III期试验；在晚期小细胞肺癌三线及以上II期剂量优化试验中，10mg每两周一次组确认ORR为53． 3％、mPFS达7．03个月，6个月及12个月OS率分别为83．2％及69．1％；治疗神经内分泌癌推荐剂量 组全人群确认ORR38．5％，DLL3阳性患者达66．7％。 注射用ZG005正推进单药及联合用药治疗肝癌、神经内分泌癌、宫颈癌等试验；二线及以上宫颈癌 20mg／kg Q3W方案确认ORR40．9％、DCR68．2％、mPFS超11个月，联合方案一线宫颈癌及早期肝 癌 ...

Core Viewpoint - Company announced a collaboration with WuXi AppTec to enhance its drug development capabilities and reduce clinical trial time and costs [1] Group 1 - Company’s subsidiary, Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd., signed a technical service contract with WuXi AppTec [1] - The collaboration is expected to expand the company's drug research and development capacity [1] - The agreement aims to ensure the smooth progress of projects by saving time and costs associated with clinical trials [1]

Core Viewpoint - Fosun Pharma has signed a licensing agreement with Expedition for the global development, production, and commercialization of the investigational product XH-S004, excluding mainland China and Hong Kong and Macau [1] Group 1: Licensing Agreement Details - The agreement allows Expedition to develop and commercialize XH-S004 globally, while Fosun Pharma retains rights for development and commercialization in mainland China and Hong Kong and Macau [1] - Expedition will pay up to $120 million in non-refundable upfront payments and milestone payments related to development and regulatory achievements [1] - Additionally, Expedition may pay up to $525 million in sales milestone payments based on annual net sales performance of the licensed product in the licensed regions [1] Group 2: Product Information - XH-S004 is a small molecule oral DPP-1 inhibitor developed by Fosun Pharma, aimed at reducing inflammation and blocking the cycle of infection and airway structural damage [1] - Potential indications for XH-S004 include non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease [1] Group 3: Strategic Implications - This collaboration is expected to accelerate the clinical development and commercialization of the licensed product globally [1] - The partnership will also help expand Fosun Pharma's innovative product portfolio in international markets [1]

Group 1 - The company held its 15th meeting of the 10th board of directors on May 30, 2025, with all 9 directors participating, complying with relevant laws and regulations [1] - The company plans to hold the 2024 annual shareholders' meeting on June 20, 2025, with all votes in favor [1] - The board approved amendments to the "Performance Bonus Incentive Measures" to optimize the incentive mechanism and enhance overall operational efficiency [2] Group 2 - The company’s wholly-owned subsidiary, Harbin Pharmaceutical Group Bioengineering Co., Ltd., signed a technology transfer contract with Shanghai Bozhi Research New Drug Co., Ltd., with a total contract value of 44.8 million yuan [2] - The contract includes clear terms regarding technical objectives, payment methods, and liability for breach of contract, acknowledging the uncertainties involved in drug development [3] - The company will adhere to information disclosure obligations as per the Shanghai Stock Exchange regulations [3]